TrialThe oncologist2020

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.

Lee S Schwartzberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.